表纸
市场调查报告书

子宫平滑肌瘤 (子宫肌瘤):开发中产品分析

Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H1 2020

出版商 Global Markets Direct 商品编码 912072
出版日期 内容资讯 英文 113 Pages
订单完成后即时交付
价格
Back to Top
子宫平滑肌瘤 (子宫肌瘤):开发中产品分析 Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H1 2020
出版日期: 2020年01月31日内容资讯: 英文 113 Pages
简介

本报告提供全球各国子宫平滑肌瘤 (子宫肌瘤) 治疗用的开发中产品的开发情形相关分析,开发中产品的最新趋势,及临床实验的各阶段的产品一览,主要企业的简介,主要药物概要,最新的产业趋势等调查。

简介

  • 调查范围

子宫平滑肌瘤 (子宫肌瘤) - 概要

子宫平滑肌瘤 (子宫肌瘤) - 治疗药的开发

  • 开发平台概要
  • 各企业的开发平台趋势
  • 各大学、研究机关的开发平台趋势
  • 企业开发中的产品
  • 在大学、研究机关开发中的产品

子宫平滑肌瘤 (子宫肌瘤) - 治疗药的评估

  • 各标的
  • 各作用机制
  • 各给药途径
  • 各分子类型

子宫平滑肌瘤 (子宫肌瘤)的开发治疗药的企业

  • AbbVie Inc
  • Addex Therapeutics Ltd
  • Auritec Pharmaceuticals Inc
  • Bayer AG
  • BioSpecifics Technologies Corp
  • GeneScience Pharmaceuticals Co Ltd
  • Immunitor Inc
  • Kissei药品
  • Livzon Pharmaceutical Group Co Ltd
  • Luye Pharma Group Ltd
  • Richter Gedeon Nyrt
  • 武田药品工业

药物简介

子宫平滑肌瘤 (子宫肌瘤) - 暂停中的计划

子宫平滑肌瘤 (子宫肌瘤) - 开发中止的产品

子宫平滑肌瘤 (子宫肌瘤) - 产品开发里程碑

  • 主要消息和新闻稿

附录

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: GMDHC11918IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H1 2020, provides an overview of the Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) pipeline landscape.

Uterine fibroids are benign tumors that originate in the uterus (womb). Although they are composed of the same smooth muscle fibers as the uterine wall (myometrium), they are much denser than normal myometrium. Uterine fibroids are usually round. The most common symptoms of uterine fibroids include heavy menstrual bleeding, prolonged menstrual periods seven days or more of menstrual bleeding, pelvic pressure or pain, frequent urination, difficulty emptying bladder, constipation and backache or leg pains.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) pipeline guide also reviews of key players involved in therapeutic development for Uterine Leiomyoma (Uterine Fibroids) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Unknown stages are 2, 3, 1, 3, 4 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders).
  • The pipeline guide reviews pipeline therapeutics for Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Introduction

  • Uterine Leiomyoma (Uterine Fibroids) - Overview
  • Uterine Leiomyoma (Uterine Fibroids) - Therapeutics Development
  • Uterine Leiomyoma (Uterine Fibroids) - Therapeutics Assessment
  • Uterine Leiomyoma (Uterine Fibroids) - Companies Involved in Therapeutics Development
  • Uterine Leiomyoma (Uterine Fibroids) - Drug Profiles
  • Uterine Leiomyoma (Uterine Fibroids) - Dormant Projects
  • Uterine Leiomyoma (Uterine Fibroids) - Discontinued Products
  • Uterine Leiomyoma (Uterine Fibroids) - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Uterine Leiomyoma (Uterine Fibroids), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Uterine Leiomyoma (Uterine Fibroids) - Pipeline by AbbVie Inc, H1 2020
  • Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Auritec Pharmaceuticals Inc, H1 2020
  • Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Bayer AG, H1 2020
  • Uterine Leiomyoma (Uterine Fibroids) - Pipeline by BioSpecifics Technologies Corp, H1 2020
  • Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Context Therapeutics LLC, H1 2020
  • Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Evestra Inc, H1 2020
  • Uterine Leiomyoma (Uterine Fibroids) - Pipeline by GeneScience Pharmaceuticals Co Ltd, H1 2020
  • Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Immunitor Inc, H1 2020
  • Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Kissei Pharmaceutical Co Ltd, H1 2020
  • Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Livzon Pharmaceutical Group Co Ltd, H1 2020
  • Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Luye Pharma Group Ltd, H1 2020
  • Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Richter Gedeon Nyrt, H1 2020
  • Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020
  • Uterine Leiomyoma (Uterine Fibroids) - Pipeline by TiumBio Co Ltd, H1 2020
  • Uterine Leiomyoma (Uterine Fibroids) - Dormant Projects, H1 2020
  • Uterine Leiomyoma (Uterine Fibroids) - Dormant Projects, H1 2020 (Contd..1), H1 2020
  • Uterine Leiomyoma (Uterine Fibroids) - Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development for Uterine Leiomyoma (Uterine Fibroids), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Targets, H1 2020
  • Number of Products by Stage and Targets, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
Back to Top